Metastatic Prostate Cancer – Pipeline Insight, 2026

DelveInsight’s “Metastatic Prostate Cancer – Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies developing 85+ pipeline drugs in the metastatic prostate cancer (mPC) pipeline landscape, covering clinical and nonclinical stage products along with therapeutic assessment by product type, stage, route of administration, and molecule type, and further highlighting inactive pipeline products in this space.​

Explore the latest developments in the Metastatic Prostate Cancer pipeline today @ https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Metastatic Prostate Cancer Pipeline Report​

• In January 2026, Alliance A032304 (RECIPROCAL) Phase 3 trial launched to optimize PSMA-RLT timing in mCRPC to reduce toxicity.

• In January 2026, ARTBIO dosed first patients in Phase 1 ARTISAN trial of AB001 (alpha radioligand, PSMA-targeted) in mCRPC.

• In December 2025, the FDA granted regular approval to rucaparib (Rubraca) for BRCAm-associated mCRPC post-ARPI (based on TRITON3 Phase 3).

• In October 2025, GSK entered $357M exclusive license agreement with Syndivia for ADC targeting mCRPC using GeminiMab platform.

• In August 2025, the FDA granted Fast Track designation to HLD-0915 (Halda Therapeutics) for mCRPC.

• In July 2025, AB Science announced FDA/EMA authorization for confirmatory Phase III trial of masitinib in mCRPC (biomarker-selected, less advanced disease).

• Key metastatic prostate therapies and companies: Opevesostat (Merck), AZD5305 (AstraZeneca), SX-682 (Syntrix), Onvansertib (Cardiff Oncology), JANX007 (Janux), ORIC-944 (ORIC Pharmaceuticals), Mevrometostat (Pfizer), Capivasertib (AstraZeneca), ARV-110 (Arvinas), MGC018 (MacroGenics), DS-7300 (Daiichi Sankyo), PSMA [Lu-177]-PNT2002 (Point Biopharma), EPI-7386 (Essa Pharma), and others.

Download for updates and the latest evolution in Metastatic Prostate Cancer care @ Metastatic Prostate Cancer Clinical Trials Assessment

Metastatic Prostate Cancer Emerging Drugs Profile​s

• Opevesostat: Merck​

Opevesostat is an oral, non-steroidal, selective inhibitor of the CYP11A1 enzyme (discovered and developed by Orion) intended to suppress production of steroid hormones and precursors that can activate androgen receptor signaling, and it is in Phase III development for metastatic prostate cancer per the page.​

• AZD5305: AstraZeneca​

AZD5305 is described as a potent, selective PARP1 inhibitor (with 500-fold selectivity for PARP1 over PARP2) designed to drive lethal DNA damage accumulation particularly in cells with HRR pathway deficiencies, and it is in Phase III development for metastatic prostate cancer per the page.​

• SX-682: Syntrix Pharmaceuticals

SX-682 is a potent small-molecule dual-inhibitor of CXCR1 and CXCR2, chemokine receptors pivotal to myeloid cell suppression of cancer surveillance by the adaptive immune system. By blocking the CXCR1/2 pathway, SX-682 inactivates immunosuppressive myeloid cells, thereby cutting off “at the source” dozens of downstream pro-tumor mechanisms mediated by these cells. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Prostate Cancer.

For more information on the Metastatic Prostate Cancer Emerging Drugs Profile, download DelveInsight’s comprehensive Metastatic Prostate Cancer Pipeline Insight report.

The Metastatic Prostate Cancer Pipeline Report Provides​

• A detailed picture of the metastatic prostate cancer pipeline landscape, including disease overview and treatment guidelines noted on the page.​

• An assessment that includes in-depth commercial and clinical evaluation of pipeline products under development, including mechanism of action, clinical studies, and product development activities such as collaborations, licensing, funding, and designations (as applicable).​

• Coverage of therapies across Phase III, Phase II, Phase I, preclinical, and discovery stages, along with inactive/discontinued products as stated on the page.​

• Therapeutic segmentation by route of administration and molecule type, as outlined in the therapeutic assessment section on the page.​

• Report insights that include pipeline analysis, therapeutic assessment, unmet needs, and impact of drugs, as listed on the page.​

Learn more about Metastatic Prostate Cancer Drugs opportunities in our comprehensive Metastatic Prostate Cancer pipeline report @ Metastatic Prostate Cancer Unmet Needs

Metastatic Prostate Cancer Companies​

There are 80+ key companies developing therapies for metastatic prostate cancer, and companies mentioned on the page in connection with specific emerging therapies include Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, and ORIC Pharmaceuticals, Inc., among others.​

DelveInsight’s metastatic prostate cancer pipeline report provides the therapeutic assessment of pipeline drugs by the Route of Administration; products have been categorized under various ROAs such as:​

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Metastatic prostate cancer products have been categorized under various molecule types such as:​

• Recombinant fusion proteins​

• Small molecule​

• Monoclonal antibody​

• Peptide​

• Polymer​

• Gene therapy​

Discover the latest advancements in Metastatic prostate cancer treatment by visiting our website. Stay informed @ Metastatic Prostate Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Prostate Cancer Pipeline Report​

• Coverage: Global​

• Metastatic prostate cancer companies: AstraZeneca, Arvinas, Daiichi Sankyo, Essa Pharma, Janssen, Pfizer, Astellas Pharma, Bayer, Bristol Myers Squibb, Merck, MacroGenics, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, Novartis, and Sanofi among others.​

• Metastatic prostate cancer therapeutic assessment by product type: Mono, Combination, and Mono/Combination.​

• Metastatic prostate cancer therapeutic assessment by clinical stages: Phase III, Phase II, Phase I, Preclinical, and Discovery (with additional mention of discontinued & inactive candidates).​

Table of Contents

1. Introduction

2. Executive Summary

3. Metastatic Prostate Cancer: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Metastatic Prostate Cancer – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Metastatic Prostate Cancer Key Companies

13. Metastatic Prostate Cancer Key Products

14. Metastatic Prostate Cancer Unmet Needs

15. Metastatic Prostate Cancer Market Drivers and Barriers

16. Metastatic Prostate Cancer Future Perspectives and Conclusion

17. Metastatic Prostate Cancer Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services